Last update 21 Mar 2024

Argyria

Last update 21 Mar 2024

Basic Info

Synonyms

ARGYRIA, Argyria, Argyria

+ [23]

Introduction

A permanent ashen-gray discoloration of the skin, conjunctiva, and internal organs resulting from long-continued use of silver salts. (Dorland, 27th ed)

Clinical Trials associated with Argyria

NCT04463316 / RecruitingNot Applicable

GROWing Up With Rare GENEtic Syndromes ….When Children With Complex Genetic Syndromes Reach Adult Age

Introduction Rare complex syndromes Patients with complex genetic syndromes, by definition, have combined medical problems affecting multiple organ systems, and intellectual disability is often part of the syndrome. During childhood, patients with rare genetic syndromes receive multidisciplinary and specialized medical care; they usually receive medical care from 3-4 medical specialists.
Increased life expectancy Although many genetic syndromes used to cause premature death, improvement of medical care has improved life expectancy. More and more patients are now reaching adult age, and the complexity of the syndrome persists into adulthood. However, until recently, multidisciplinary care was not available for adults with rare genetic syndromes. Ideally, active and well-coordinated health management is provided to prevent, detect, and treat comorbidities that are part of the syndrome. However, after transition from pediatric to adult medical care, patients and their parents often report fragmented poor quality care instead of adequate and integrated health management. Therefore, pediatricians express the urgent need for adequate, multidisciplinary adult follow up of their pediatric patients with rare genetic syndromes.
Medical guidelines for adults not exist and the literature on health problems in these adults is scarce. Although there is a clear explanation for the absence of adult guidelines (i.e. the fact that in the past patients with rare genetic syndromes often died before reaching adult age), there is an urgent need for an overview of medical issues at adult age, for 'best practice' and, if possible, for medical guidelines.
The aim of this study is to get an overview of medical needs of adults with rare genetic syndromes, including:
1. comorbidities
2. medical and their impact on quality of life
3. medication use
4. the need for adaption of medication dose according to each syndrome
Methods and Results This is a retrospective file study. Analysis will be performed using SPSS version 23 and R version 3.6.0.

Start Date01 Oct 2018

Sponsor / Collaborator

Erasmus Medical Center (Private Equity)

NCT01755052 / CompletedNot ApplicableIIT

SILVER-AMI: Risk Stratification in Older Persons With Acute Myocardial Infarction

SILVER-AMI is a research study of older persons who are admitted to the hospital with a heart attack. Patients will be interviewed in the hospital and again 6 months later. The researchers will also collect detailed medical record information to understand the effect of heart attacks on older persons.
The research team at Yale University will use this information to develop a risk model that can be used to help doctors predict recovery. The goal of the study is to help older people in the future make well-informed decisions about their health care during a heart attack.

Start Date01 Jan 2013

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Argyria

100 Translational Medicine associated with Argyria

0 Patents (Medical) associated with Argyria

362

Literatures (Medical) associated with Argyria

10 Jan 2024·ACS applied bio materials

Smart Nanofibrous Hydrogel Wound Dressings for Dynamic Infection Diagnosis and Control: Soft but Functionally Rigid.

Article

Author: Raj Kumar Sen ; Priyanka Prabhakar ; Shruti ; Priya Verma ; Apeksha Vikram ; Aradhana Mishra ; Ashish Dwivedi ; Vijay Sorna Gowri ; Jamuna Prasad Chaurasia ; Dehi Pada Mondal ; Avanish Kumar Srivastava ; Neeraj Dwivedi ; Chetna Dhand

Chronic wounds, such as burns and diabetic foot ulcers, pose significant challenges to global healthcare systems due to prolonged hospitalization and increased costs attributed to susceptibility to bacterial infections. The conventional use of antibiotic-loaded and metal-impregnated dressings exacerbates concerns related to multidrug resistance and skin argyrosis. In response to these challenges, our research introduces a unique approach utilizing antibiotic-free smart hydrogel wound dressings with integrated infection eradication and diagnostic capabilities. Electrospinning stands out as a method capable of producing hydrogel nanofibrous materials possessing favorable characteristics for treating wounds and detecting infections under conditions utilizing sustainable materials. In this study, innovative dressings are fabricated through electrospinning polycaprolactone (PCL)/gelatin (GEL) hybrid hydrogel nanofibers, incorporating pDA as a cross-linker, εPL as a broad-spectrum antimicrobial agent, and anthocyanin as a pH-responsive probe. The developed dressings demonstrate exceptional antioxidant (>90% radical scavenging) and antimicrobial properties (95-100% killing). The inclusion of polyphenols/flavonoids and εPL leads to absolute bacterial eradication, and in vitro assessments using HaCaT cells indicate increased cell proliferation, decreased reactive oxygen species (ROS) production, and enhanced cell viability (100% Cell viability). The dressings display notable alterations in color that correspond to different wound conditions. Specifically, they exhibit a red/violet hue under healthy wound conditions (pH 4-6.5) and a green/blue color under unhealthy wound conditions (pH > 6.5). These distinctive color changes provide valuable insights into the versatile applications of the dressings in the care and management of wounds. Our findings suggest that these antibiotic-free smart hydrogel wound dressings hold promise as an effective and sustainable solution for chronic wounds, providing simultaneous infection control and diagnostic monitoring. This research contributes to advancing the field of wound care, offering a potential paradigm shift in the development of next-generation wound dressings.

26 Dec 2023·The American Journal of dermatopathology

Localized Cutaneous Argyria at the Site of a Prior Melanoma Excision Confirmed by Scanning Electron Microscopy With Energy Dispersive X-ray Analysis.

Article

Author: Shane P McTighe ; Elizabeth A Taylor ; Jill Allbritton ; Michael R Lewin-Smith

ABSTRACT:

Localized cutaneous argyria is a rare condition caused by the accumulation of silver particles in the skin, leading to blue-gray discoloration. Argyria may mimic melanoma and lead to misdiagnosis. We present a patient with a history of melanoma that developed a blue-gray nodule at a prior melanoma graft. The diagnosis was confirmed using scanning electron microscopy and energy dispersive x-ray analysis. These techniques differentiate argyria from melanoma and can be performed on formalin-fixed, paraffin-embedded, tissue sections. Health care providers should be alert that argyria may mimic recurrent melanoma in patients unaware of silver exposure.

30 May 2023·Journal of orthopaedic surgery and research

First clinical experience with posterior lumbar interbody fusion using a thermal-sprayed silver-containing hydroxyapatite-coated cage.

Article

Author: Tadatsugu Morimoto ; Masatsugu Tsukamoto ; Katsuhiro Aita ; Nobuyuki Fujita ; Masaaki Mawatari

BACKGROUND:

To investigate the possibility of silver (Ag)-induced adverse events and the degree of bone fusion in posterior lumbar interbody fusion surgery using an Ag-containing hydroxyapatite (HA) lumbar interbody cage.

METHODS:

An Ag-HA cage consisting of highly osteoconductive HA interfused with Ag was developed, and we applied it clinically at three university-affiliated hospitals from April 2020 to December 2020. During the 12-month postoperative observation period, Ag-related adverse events, neuropathy, and postoperative complications were investigated as indicators of safety, while clinical improvement and the fusion status were investigated as indicators of efficacy. Clinical improvement was defined as improvement beyond the minimum clinically important difference (MCID) in the numerical rating scale (NRS; 1.6) for low back and lower limb pain and the Oswestry Disability Index (ODI; 12.8).

RESULTS:

We performed lumbar interbody fusion using an Ag-HA cage for 48 patients (female, n = 25; mean age, 67.5 years). The mean preoperative NRS was 6.4 (standard deviation, 1.9), while the mean preoperative ODI was 44 [12]. No adverse effects (i.e., argyria) were identified during the 12-month observation period. Surgical site infection occurred in one case, although the implant was preserved via immediate debridement. In total, 39 (81%) participants showed clinical improvement beyond MCID for both NRS and ODI. Bone fusion was achieved at 45 levels (88%) at 6 months and 48 levels (91%) at 12 months postoperatively.

CONCLUSIONS:

The results of this study suggest that Ag-HA cages can be safely used in spinal fusion procedures and have the potential to prevent postoperative infections, prevent deterioration of the quality of life, and result in favorable outcomes. Larger-scale and longer-term follow-up studies will be required to corroborate these conclusions. Trial registration UMIN 000039964 (date: April 01, 2020).

News (Medical) associated with Argyria

24 Oct 2023

·www.prnewswire.com

Walgreens and CVS Under Investigation by FDA for Selling Unapproved--and Potentially Unsafe--Eye Drop Products

Walgreens and CVS Eye Drop Purchasers are Urged to Contact Schubert Jonckheer & Kolbe to Discuss Their Legal Rights SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP has launched an investigation into Walgreens and CVS after the U.S. Food & Drug Administration issued warning letters to manufacturers of eye drop products. Walgreens and CVS marketed certain non-FDA approved eye drop products as treatment for medical conditions. These products include: Walgreens Allergy Eye Drops Walgreens Stye Eye Drops Walgreens Pink Eye Drops CVS Health Brand Pink Eye Relief Eye Drops Walgreens and CVS marketed certain eye drop products as treatments for medical conditions such as conjunctivitis, cataracts, and glaucoma. However, according to the FDA, these products are "drugs" under the Food, Drug, & Cosmetic Act, which. defines drugs as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals." On September 12, 2023, the FDA announced that it was "particularly concerned that these illegally marketed, unapproved ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses". In its warning letter to Walgreens, the FDA noted that Walgreen's ophthalmic drug products utilize silver sulfate as a preservative. This is a concern because long term use of medicinal compounds containing silver may cause argyria (a blueish-gray discoloration of the skin and eyes that is irreversible). It may also cause adverse effects on night vision. In light of these concerns, the Schubert Firm is investigating whether CVS and Walgreens have violated state and federal laws by selling unapproved—and potentially unsafe—eye drop products. If you purchased one of these products, you may be entitled to a refund and an injunction requiring CVS and Walgreens to stop selling them. If you have purchased any of the above eye drops from CVS and Walgreens and wish to obtain additional information about your legal rights, please contact us today or visit our website at . About Schubert Jonckheer & Kolbe LLP Schubert Jonckheer & Kolbe represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide. Contact Amber L. Schubert Schubert Jonckheer & Kolbe LLP [email protected] Tel: (415) 788-4220 SOURCE Schubert Jonckheer & Kolbe LLP

Analysis

Perform a panoramic analysis of this field.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Argyria

Basic Info

Related

Analysis